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Possible time trends were investigated by analyzing the 
derived PP motion from daily CBCTs as a function of 
treatment day. The reproducibility of the PP motion was 
measured as the standard deviation (SD) over the mean PP 
motion per patient. We used a linear regression model to 
analyse the relationship between these outcomes and age 
and height.  
 
Results: Over all patients, PP motion was on average 8.6 mm 
(range 4-15 mm) and varied largely within and between 
patients. Time trends differed between patients. PP motion 
correlated with age and height (p<0.05). PP motion increased 
by 0.42 mm for every yearly increase in patients’ age and for 
every 1 cm increase in height the PP motion increased 0.07 
mm (Figure 1). The SD ranged from 1-3.7 mm and correlated 
with age and height (p<0.05) (Figure 1). 
 
 
 
Conclusion: Respiration-induced diaphragmatic motion in 
children during IGRT is correlated with age and height, 
however irregular breathing patterns were found. PP motion 
was variable throughout the treatment. Therefore, 
introducing child-friendly breathing exercises and/or 
coaching techniques may be beneficial to minimize PP motion 
and to enhance its reproducibility.  
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Purpose or Objective: Second malignant neoplasms (SMNs) 
are a concern in survivors of childhood cancer. Chemotherapy 
forms the mainstay of treatment for acute lymphoblastic 
leukaemia (ALL), but radiotherapy has a role in certain 
situations. As both chemotherapy and radiotherapy can be 
carcinogenic, patients treated with both modalities may be 
at a higher risk of SMNs. This study aims to investigate the 
incidence of SMNs in patients treated with both 
chemotherapy and radiotherapy at KK Women's and Children's 
Hospital, Singapore. 
 
Material and Methods: We performed a retrospective review 
of ALL patients treated in the largest maternal and children's 
hospital in Singapore. Children aged 16 years and below 
diagnosed with ALL from 1993 to 2014 were identified in the 
Childhood Cancer Registry. Manual and electronic medical 
records were reviewed for information on demographics, 
management and SMNs. 
 
Results: A total of 64 patients treated with both 
chemotherapy and radiotherapy were identified. Seventeen 
(26.6%) were female and 47 (73.4%) were male. The median 
follow-up was 9.2 years (range, 1.1-22.0 years). The median 
age at diagnosis was 5.3 years (range, 0.3-14.6 years). The 
median age at which radiotherapy was given was 6.6 years 
(range, 2.9-15.4 years).  
SMNs were noted in 3 of 64 (4.7%) patients. Two of 3 patients 
had a SMN within the radiation field (both cranial). The 
histological diagnoses were basal cell carcinoma and cerebral 
PNET. The remaining patient had an ovarian immature 
teratoma outside the radiation field. The median latency 
period was 9.4 years (range, 8.3-13.3 years) from date of 
diagnosis to development of SMN. The estimated 10-year 
cumulative incidence was 4.3%, 95% CI [0.01, 0.13] using a 
competing risks analysis.  
Radiotherapy data was available in 63 patients. Fifty-one of 
63 (81.0%) received cranial irradiation, of which 3 (5.9%) also 
received spinal irradiation. Total body irradiation was 
performed in 20 of 63 (31.7%), and testicular irradiation in 17 
of 63 (27.0%) patients. The orbit was targeted in 3 of 63 
(4.8%) patients. 
 
Conclusion: Long term survivors of ALL treated with both 
chemotherapy and radiotherapy may have a significant risk of 
second malignant neoplasms, which may occur years after 
the initial diagnosis. 
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Purpose or Objective: An intensity-modulated radiation 
therapy technique for craniospinal irradiation (IMRT-CSI) 
delivered on the Tomotherapy unit has been used at our 
centre since 2008. Defining and prioritizing dose constraints 
to target and organs at risk (OAR) are time-consuming. To 
facilitate and standardize the planning process, we 
developed a dose-volume histogram (DVH) registry and tested 
its usefulness with two cohorts of patients treated to 
different doses of CSI.  
 
Material and Methods: The registry consists of a back-end 
MySQL database and front-end webpages that are served via 
a web-server internal to the clinic. Approved plans are added 
to the DVH registry via a filter that standardizes the names of 
the OARs. Dose constraints for planning are established based 
on previous aggregate data and planners graphically compare 
DVH data for a new treatment plan with existing aggregate 
data without submitting the new data to the registry. We 
evaluated two cohorts of IMRT-CSI patients: (1) CSI dose 36 
Gy in 20 fractions and (2) CSI dose 23.4 Gy in 13 fractions and 
compared the findings with an earlier cohort of patients that 
were planned before we started using the registry. 
 
Results: Eighteen patients, age 3 to 17 years, were included 
in the registry. Eleven were treated to a dose of 36 Gy in 20 
fractions and seven to a dose of 23.4 Gy in 13 fractions. Most 
(56%) had medulloblastoma. Significantly smaller variations 
were achieved for OAR for patients treated at 36 Gy using the 
DVH registry compared with patients in the earlier cohort, 
making the registry a very useful tool for the treating team. 
V20 were lower for all OARs except the trachea. 
 
Conclusion: The results confirm that the DVH registry 
standardizes the planning process of IMRT-CSI patients. We 
will use constraints obtained from the 7 patients treated at 
23.4 Gy to start planning new cases and evaluate the benefit 
of our DVH registry for this regimen. 
 
 
 
 
 
